BidaskClub upgraded shares of Amyris (NASDAQ:AMRS) from a strong sell rating to a sell rating in a research report report published on Friday, BidAskClub reports.

A number of other equities analysts also recently issued reports on the company. Oppenheimer began coverage on Amyris in a research note on Wednesday, December 11th. They set an outperform rating and a $8.00 price target for the company. HC Wainwright restated a buy rating and issued a $11.00 target price on shares of Amyris in a research note on Friday, October 11th. Finally, Zacks Investment Research downgraded Amyris from a buy rating to a hold rating in a research note on Wednesday, January 8th.

AMRS stock opened at $2.97 on Friday. The company has a market capitalization of $313.34 million, a P/E ratio of -0.95 and a beta of 0.89. Amyris has a 52-week low of $1.87 and a 52-week high of $6.06. The business has a 50-day simple moving average of $3.21 and a two-hundred day simple moving average of $3.63.

Amyris (NASDAQ:AMRS) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.02. The company had revenue of $34.95 million for the quarter, compared to analyst estimates of $21.60 million. Equities research analysts expect that Amyris will post -2.36 earnings per share for the current year.

In other news, Director Patrick Y. Yang sold 10,671 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $3.10, for a total value of $33,080.10. Following the transaction, the director now owns 43,527 shares in the company, valued at approximately $134,933.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 30.40% of the stock is owned by insiders.

Several large investors have recently bought and sold shares of the stock. BlackRock Inc. raised its holdings in shares of Amyris by 15.2% in the 2nd quarter. BlackRock Inc. now owns 3,709,099 shares of the biotechnology company’s stock worth $13,204,000 after purchasing an additional 488,491 shares during the period. Vanguard Group Inc. grew its position in shares of Amyris by 15.9% during the 2nd quarter. Vanguard Group Inc. now owns 2,373,116 shares of the biotechnology company’s stock valued at $8,448,000 after purchasing an additional 325,775 shares in the last quarter. State Street Corp grew its position in shares of Amyris by 5.5% during the 3rd quarter. State Street Corp now owns 669,921 shares of the biotechnology company’s stock valued at $3,189,000 after purchasing an additional 35,126 shares in the last quarter. Northern Trust Corp grew its position in shares of Amyris by 3.4% during the 2nd quarter. Northern Trust Corp now owns 417,413 shares of the biotechnology company’s stock valued at $1,486,000 after purchasing an additional 13,691 shares in the last quarter. Finally, Barclays PLC grew its position in shares of Amyris by 461.0% during the 3rd quarter. Barclays PLC now owns 371,193 shares of the biotechnology company’s stock valued at $1,767,000 after purchasing an additional 305,029 shares in the last quarter. 28.61% of the stock is currently owned by institutional investors.

Amyris Company Profile

Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.

Featured Article: Accumulation/Distribution

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.